H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Checkpoint Therapeutics with a $76 price target after the company announced the expected Biologics License Applications filing for cosibelimab, encompassing both metastatic or locally advanced cutaneous squamous cell carcinoma. The filing is the beginning of creating a "transformative shift" in Checkpoint’s thesis, Pantginis tells investors in a research note. He thinks an FDA panel meeting is "highly unlikely" as Checkpoint’s path to commercialization "begins in earnest." Cosibelimab’s profile could be appealing to future combination regimens, and could even bring Merck (MRK or Bristol-Myers Squibb (BMY) "to the table," contends Pantginis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CKPT:
- Checkpoint Therapeutics’ BLA submission positive news, says Cantor Fitzgerald
- Checkpoint Therapeutics submits BLA to FDA for cosibelimab
- Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Checkpoint price target adjusted to $76 at H.C. Wainwright after reverse split
- Checkpoint Therapeutics price target raised to $15 from $7 at B. Riley